J&J's Monistat 3 Rx-to-OTC switch approved by FDA; launch expected in early May.
This article was originally published in The Tan Sheet
Executive Summary
OTC MONISTAT 3 WILL BE ON STORE SHELVES BY EARLY MAY, Johnson & Johnson subsidiary Advanced Care Products announced on April 23. FDA approved J&J's Rx-to-OTC switch application for the three-day miconazole nitrate vaginal yeast infection regimen on April 16. The launch of Monistat 3 Combination Pack will be accompanied by advertising campaigns targeted at both consumers and professionals, J&J said.